Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBT: 2017-2024

Historic EBT for Apellis Pharmaceuticals (APLS) over the last 8 years, with Dec 2024 value amounting to -$196.7 million.

  • Apellis Pharmaceuticals' EBT rose 480.48% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year increase of 118.84%. This contributed to the annual value of -$196.7 million for FY2024, which is 62.64% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' EBT is -$196.7 million, which was up 62.64% from -$526.5 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' EBT registered a high of -$196.7 million during FY2024, and its lowest value of -$746.0 million during FY2021.
  • In the last 3 years, Apellis Pharmaceuticals' EBT had a median value of -$526.5 million in 2023 and averaged -$458.2 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' EBT tumbled by 117.47% in 2021, and later skyrocketed by 62.64% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' EBT (Yearly) stood at -$343.0 million in 2020, then crashed by 117.47% to -$746.0 million in 2021, then climbed by 12.67% to -$651.5 million in 2022, then increased by 19.19% to -$526.5 million in 2023, then soared by 62.64% to -$196.7 million in 2024.